Q-omics provides the consensus-scored CLEC20A profile across patient tissues and cancer cell-line models. CLEC20A expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CLEC20A is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, CLEC20A RNA expression shows 4,057 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight HNSC, and KIRC as cancer lineages where CLEC20A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC20A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC20A survival associations across molecular data types. CLEC20A RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC20A RNA expression–survival associations across cancer types. High CLEC20A expression shows unfavorable associations in KICH, ACC, LUAD, GBM and STAD, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify HNSC as the clearest survival context for CLEC20A RNA expression.
This table summarizes CLEC20A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CLEC20A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC20A shows lower tumor expression in KIRC and KICH. The KIRC box plot shows higher CLEC20A RNA expression in normal versus tumor tissue (log2 FC = −0.020, t-test p < 0.001).
This table shows molecular features associated with CLEC20A in patient tissues and cancer cell lines. In patient samples, CLEC20A shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC20A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
